Content Hub

+

2-year outcomes from the TRILUMINATE Pivotal trial

New TriClip TEER data released - TRILUMINATE Pivotal trial 2-year outcomes, proving TriClip TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) at 2-years, while confirming its exceptional safety and effectiveness.

Download

LEARN MORE:

CLINICAL DATA PCR London Valves 2024

Related Resources

TRENDING TOPICS

Valvular Heart Disease Guidelines at a Glance

Explore the Latest VHD Guideline Updates for Mitral and Tricuspid Regurgitation

Immediate Relief. Durable Benefits

MitraClip™ TEER Delivers Durable MR Reduction and Long-Term Patient Benefits

Reduced HF Hospitalisation. Improved Quality of Life

MitraClip™ TEER Reduces HF Hospitalisations and Improves Patient Outcomes

Der Inhalt dieser Website richtet sich an medizinisches Fachpersonal in der EMEA mit entsprechender Produktregistrierung durch die Gesundheitsbehörde, mit Ausnahme derjenigen, die in Frankreich praktizieren, da einige der Inhalte nicht mit dem französischen Werbegesetz N°2011-2012 vom 29. Dezember 2011, Artikel 34, übereinstimmen. Klicken Sie auf OK, um zu bestätigen, dass Sie Angehöriger eines Gesundheitsberufs sind, um fortzufahren.

OK ablehnen

2-year outcomes from the TRILUMINATE Pivotal trial

Related Resources

TRENDING TOPICS

Valvular Heart Disease Guidelines at a Glance

Immediate Relief. Durable Benefits

Reduced HF Hospitalisation. Improved Quality of Life

CONNEXT

Procedural tip & tricks with Navitor across all valve sizes

Transcatheter Aortic Valves Implant

1-year VANTAGE TAVI outcomes in low/intermediate-risk patients

A Defining Moment Has To Start Somewhere. Why Not With You?

CONNEXT

Procedural tip & tricks with Navitor across all valve sizes

Transcatheter Aortic Valves Implant

Transcatheter tricuspid valve repair: Cases, tips and tricks

M-TEER: Best treatment strategies for FMR AND DMR